Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 2017, Article ID 5180984, 6 pages
https://doi.org/10.1155/2017/5180984
Research Article

In Vitro Susceptibility of Mycobacterium ulcerans Isolates to Selected Antimicrobials

1Department of Medical Laboratory Sciences, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana
2Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana
3Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana

Correspondence should be addressed to Enid Owusu; moc.oohay@51usuwodine

Received 7 January 2017; Revised 17 February 2017; Accepted 23 February 2017; Published 14 March 2017

Academic Editor: Pietro Mastroeni

Copyright © 2017 Enid Owusu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. S. Walsh, F. Portaels, and W. M. Meyers, “Recent advances in leprosy and Buruli ulcer (Mycobacterium ulcerans infection),” Current Opinion in Infectious Diseases, vol. 23, no. 5, pp. 445–455, 2010. View at Publisher · View at Google Scholar
  2. D. J. P. Barker, “Epidemiology of Mycobacterium ulcerans infection,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 67, no. 1, pp. 43–47, 1973. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Aiga, T. Amano, S. Cairncross, J. A. Domako, O.-K. Nanas, and S. Coleman, “Assessing water-related risk factors for Buruli ulcer: a case-control study in Ghana,” American Journal of Tropical Medicine and Hygiene, vol. 71, no. 4, pp. 387–392, 2004. View at Google Scholar · View at Scopus
  4. G. Amofah, F. Bonsu, C. Tetteh et al., “Buruli ulcer in Ghana: results of a national case search,” Emerging Infectious Diseases, vol. 8, no. 2, pp. 167–170, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. World Health Organization, W.H.O. Joins Battle against a New Emerging Disease, Buruli ulcer, Press Release WHO/88, World Health Organization, Geneva, Switzerland, 1997.
  6. L. Marsollier, J. Aubry, J.-P. Saint-André et al., “Ecology and transmission of Mycobacterium ulcerans,” Pathologie Biologie, vol. 51, no. 8-9, pp. 490–495, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. World Health Organization, Buruli ulcer: Diagnosis of Mycobacterium ulcerans Disease: A Manual for Health Care Providers, edited by F. Portaels, P. Johnson, and W. M. Meyers, WHO/CDS/CPE/GBUI/2001.4, World Health Organization, Geneva, Switzerland, 2001.
  8. P. Agbenorku, M. Agbenorku, R. Adator, L. Tuuli, and E. Brobbey, “Basic plastic surgery skills for district and community doctors to manage Buruli ulcer in Ghana,” Annals of African Medicine, vol. 4, no. 1, pp. 35–38, 2005. View at Google Scholar · View at Scopus
  9. S. Etuaful, B. Carbonnelle, J. Grosset et al., “Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 8, pp. 3182–3186, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. World Health Organization, Provisional Guidance on the Role of Specific Antibiotics in the Management of Mycobacterium ulcerans disease (Buruli ulcer), WHO, Geneva, Switzerland, 2004.
  11. L. Cornet, M. Richard-Kadio, H. N'Guessan et al., “Treatment of Buruli ulcers by excision-graft,” Bulletin de la Société de Pathologie Exotique, vol. 85, pp. 355–358, 1992. View at Google Scholar
  12. P. J. Converse, E. L. Nuermberger, D. V. Almeida, and J. H. Grosset, “Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?” Future Microbiology, vol. 6, no. 10, pp. 1185–1198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. O. Adjei, M. R. W. Evans, and A. Asiedu, “Phenytoin in the treatment of Buruli ulcer,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 92, no. 1, pp. 108–109, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. R. E. Krieg, J. H. Wolcott, and W. M. Meyers, “Mycobacterium ulcerans infection: treatment with rifampin, hyperbaric oxygenation, and heat,” Aviation Space and Environmental Medicine, vol. 50, no. 9, pp. 888–892, 1979. View at Google Scholar · View at Scopus
  15. K. Asiedu and S. Etuaful, “Socioeconomic implications of Buruli ulcer in Ghana: a three-year review,” American Journal of Tropical Medicine and Hygiene, vol. 59, no. 6, pp. 1015–1022, 1998. View at Google Scholar · View at Scopus
  16. World Health Organization, “Surveillance and control of Mycobacterium ulcerans disease (Buruli ulcer),” in Fifty-Seventh World Health Assembly, Resolutions and Decisions, WHA57/2004/REC/1, pp. 1–2, WHO, Geneva, Switzerland, 2004. View at Google Scholar
  17. V. Sizaire, F. Nackers, E. Comte, and F. Portaels, “Mycobacterium ulcerans infection: control, diagnosis, and treatment,” The Lancet Infectious Diseases, vol. 6, no. 5, pp. 288–296, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Portaels, H. Traore, K. De Ridder, and W. M. Meyers, “In vitro susceptibility of Mycobacterium ulcerans to Clarithromycin,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 8, pp. 2070–2073, 1998. View at Google Scholar · View at Scopus
  19. H. S. Thangaraj, O. Adjei, B. W. Allen et al., “In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans,” Journal of Antimicrobial Chemotherapy, vol. 45, no. 2, pp. 231–233, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Chauty, M.-F. Ardant, A. Adeye et al., “Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease),” Antimicrobial Agents and Chemotherapy, vol. 51, no. 11, pp. 4029–4035, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. T. K. Hamzat and B. Boakye-Afram, “Health-related quality of life among persons living with Buruli ulcer in Amasaman Community, Ga West District Accra, Ghana,” International Journal of Health Sciences, vol. 5, no. 1, pp. 29–38, 2011. View at Google Scholar
  22. E. J. Baron, L. R. Peterson, and S. M. Finegold, Bailey and Scott's Diagnostic Microbiology, Mosby Year book Inc, St. Louis, Mo, USA, 9th edition, 1994.
  23. M. W. Bratschi, M. Bolz, L. Grize et al., “Primary cultivation: factors affecting contamination and Mycobacterium ulcerans growth after long turnover time of clinical specimens,” BMC Infectious Diseases, vol. 14, article 636, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Watt, A. Rayner, and G. Harris, “Comparative activity of azithromycin against clinical isolates of mycobacteria,” Journal of Antimicrobial Chemotherapy, vol. 38, no. 3, pp. 539–542, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. M. H. Cynamon and S. P. Klemens, “Activity of azithromycin against Mycobacterium avium infection in beige mice,” Antimicrobial Agents and Chemotherapy, vol. 36, no. 8, pp. 1611–1613, 1992. View at Publisher · View at Google Scholar · View at Scopus
  26. W. D. L. Revill, R. H. Morrow, M. C. Pike, and J. Ateng, “A controlled trial of the treatment of mycobacterium ulcerans infection with clofazimine,” The Lancet, vol. 302, no. 7834, pp. 873–877, 1973. View at Publisher · View at Google Scholar · View at Scopus
  27. D. K. Espey, G. Djomand, I. Diomande et al., “Pilot study of treatment of Buruli ulcer with rifampin and dapsone,” International Journal of Infectious Diseases, vol. 6, no. 1, pp. 60–65, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Dega, A. Bentoucha, J. Robert, V. Jarlier, and J. Grosset, “Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 10, pp. 3193–3196, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Lode, K. Borner, P. Koeppe, and T. Schaberg, “Azithromycin—review of key chemical, pharmacokinetic and microbiological features,” Journal of Antimicrobial Chemotherapy, vol. 37, pp. 1–8, 1996. View at Google Scholar · View at Scopus
  30. R. Firdaus, “Rifampicin- an overview,” International Journal of Research in Pharmacy and Chemistry, vol. 3, no. 1, p. 83, 2013. View at Google Scholar
  31. A. Bentoucha, J. Robert, H. Dega, N. Lounis, V. Jarlier, and J. Grosset, “Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 11, pp. 3109–3112, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Addo, B. Adu-Addai, M. Quartey et al., “Clinical and histopathological presentation of Buruli ulcer in experimentally infected grasscutters (Thryonomys swinderianus),” The Internet Journal of Tropical Medicine, vol. 3, no. 2, 2007. View at Google Scholar
  33. A. H. Moreno, M. F. C. da Silva, and H. R. N. Salgado, “Stability study of azithromycin in ophthalmic preparations,” Brazilian Journal of Pharmaceutical Sciences, vol. 45, no. 2, pp. 219–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. E. F. Fiese and S. H. Steffen, “Comparison of the acid stability of azithromycin and erythromycin A,” Journal of Antimicrobial Chemotherapy, vol. 25, pp. 39–47, 1990. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Timoumi, D. Mangin, R. Peczalski, F. Zagrouba, and J. Andrieu, “Stability and thermophysical properties of azithromycin dihydrate,” Arabian Journal of Chemistry, vol. 7, no. 2, pp. 189–195, 2014. View at Publisher · View at Google Scholar